When should immunosuppressants be prescribed to treat systemic vasculitides?

Internal Medicine

Volumn 42, Issue 4, 2003, Pages 313-317

  Guillevin, Loïc ^a   Pagnoux, Christian ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Immunosuppressants; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ALLERGIC PNEUMONITIS; BLADDER CANCER; BLADDER DISEASE; BLOOD DISEASE; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; FIBROSIS; HEALTH STATUS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; OVARY INSUFFICIENCY; PATHOGENESIS; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRESCRIPTION; PROGNOSIS; REVIEW; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 0038324510     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.313     Document Type: Review

References (32)

1. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe necrotizing vasculitis. N Engl J Med 301: 235-238, 1979.
2. Küssmaul A, Maier K. Über eine nicht bisher beschriebene eigenthümliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskelähmung einhergeht. Dtsch Arch Klin Med 1: 484-518, 1866.
3. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33: 1088-1093, 1990.
4. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100, 1990.
5. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33: 1101-1107, 1990.
6. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994.
7. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74: 238-253, 1995.
8. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78: 26-37, 1999.
9. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42: 421-430, 1999.
10. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488-498, 1992.
11. Guillevin L, Lhote F, Jarrousse B, et al. Treatment of Wegener's granulomatosis: a prospective trial in 50 patients comparing prednisone, pulse cyclophosphamide versus prednisone and oral cyclophosphamide. Clin Exp Rheumatol 101(S1): 43, 1995 (Abstract).
12. Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 20: 1010-1036, 1995.
13. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327: 1490-1495, 1992.
14. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81:1132-1136, 1993.
15. Rieu V, Cohen P, André MH, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 41: 290-300, 2002.
16. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75: 17-28, 1996.
17. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. French Vasculitis Study Group. Arthritis Rheum 44: 666-675, 2001.
18. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 87: 671-678, 1994.
19. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 55: 146-155, 1980.
20. Guillevin L, Fechner J, Godeau P, et al. Périartérite noueuse: étude clinique et thérapeutique de 126 malades etudiesen 23 ans. Ann Méd Interne (Paris) 136: 6-12, 1985.
21. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 36: 1290-1297, 1997.
22. Généreau T, Lortholary O, Leclerq P, et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol 33: 959-962, 1994.
23. Guillevin I, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing steroids and 6 or 12 cyclophosphamide in 65 patients. Arthritis Rheum Arthritis Care Res 49: 93-100, 2003.
24. Belfayol L, Guillevin L, Louchahi K, et al. Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. Fundam Clin Pharmacol 8: 458-462, 1994.
25. Luqmani R, Jayne D, Group EVS. A multicentre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZAREM). Arthritis Rheum 42 (Suppl): S928-S225, 1999.
26. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90: 401-409, 1997.
27. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56: 467-483, 1985.
28. Pusey CD, Rees AJ, Evans DJ, Paters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40: 757-763, 1991.
29. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315: 341-347, 1986.
30. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 6: 207-219, 1993.
31. Langford C, Talar-Williams C, Barron K, Sneller K. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remisison maintenance. Arthritis Rheum 42: 2666-2673, 1999.
32. Bartolucci P, Ramanoelina J, Cohen P, Godmer P, Le Hello C, Guillevin L. Efficacy of anti-TNF antibody infliximab against refractory systemic vasculitides. An open pilot study on 10 patients. Rheumatology (Oxford) 41: 1126-1132, 2002.